Engflag

Clopitab CV

Quick links to important sections

Clopitab CV

Clopitab CV_FR

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopitab CV

Quick Facts

Property Description
Active ingredient Atorvastatin and Clopidogrel
Form Oral Capsule or Tablet
Pharmacological class HMG-CoA Reductase Inhibitor (Statin) and Antiplatelet Agent
Common use Long-term cardiovascular risk prevention
Prescription Status Prescription Only (Rx)

What Type of Medicine is Clopitab CV? (Definition and Classification)

Clopitab CV is a prescription medicine defined as a Fixed-Dose Combination (FDC) product comprising two distinct, synthetic active ingredients: Atorvastatin and Clopidogrel. This dual-action synthetic cardiovascular medicine is delivered in a single solid oral dosage form. The product combines Atorvastatin, which belongs to the HMG-CoA reductase inhibitor class (commonly known as statins), with Clopidogrel, a thienopyridine antiplatelet agent. This FDC format is specifically engineered to simplify long-term preventative regimens for patients who require both chronic therapies.

Composition and Dual Therapeutic Purpose

The active composition includes the two internationally recognized pharmaceutical ingredients: Atorvastatin and Clopidogrel. The medication’s general therapeutic objective is to provide synergistic protection by simultaneously acting upon cholesterol metabolism and blood clotting processes. Atorvastatin is a HMG-CoA reductase inhibitor, an enzyme-blocking class highly effective in lowering lipid levels. Concurrently, Clopidogrel acts as an antiplatelet drug by preventing platelets from adhering to one another to form clots, a mechanism critical for reducing the risk of thrombotic events. This combined intervention is essential for vascular prophylaxis in high-risk adult patients, integrating the benefit of reducing low-density lipoprotein cholesterol (LDL-C) with the reduced likelihood of blood clot formation.

Regulatory References

  1. Atorvastatin and Clopidogrel Combination
  2. Clopidogrel Drug Information

What side effects are possible with Clopitab CV?

Possible Side Effects and Safety Information

The official safety profile for this medicine is characterized by a central focus on the risk of bleeding events, categorized by frequency and severity in regulatory documents. These classifications adhere to established frameworks (such as CIOMS) used by major health authorities.

Frequency-Classified Adverse Reactions

The most commonly classified adverse reactions in official labeling are related to bleeding, including haematoma, epistaxis (nosebleeds), bruising, and gastrointestinal haemorrhage. Common non-bleeding effects include gastrointestinal disturbances like diarrhoea, abdominal pain, and dyspepsia.

Less common adverse reactions documented include intracranial bleeding and mild haematological changes such as thrombocytopenia and leucopenia. Rare adverse reactions include severe neutropenia.

Serious Adverse Reactions and Systemic Concerns

The official label lists serious adverse reactions that are rare but clinically critical. These include Thrombotic Thrombocytopenic Purpura (TTP), a severe blood disorder, and rare reports of acute liver failure or hepatitis. Serious haemorrhage, including fatal bleeding and intracranial haemorrhage, is noted as a risk.

Safety Restrictions and Special Populations

Safety statements in regulatory documentation define specific limitations for use. The medicine is contraindicated in patients presenting with active pathological bleeding (e.g., peptic ulcer or intracranial haemorrhage). Furthermore, use is formally contraindicated for patients with severe hepatic impairment, severe renal impairment (creatinine clearance <30 ml/min), and during the third trimester of pregnancy. The risk of bleeding is noted in official documentation as being particularly high during the first weeks of treatment.

Overdose and Emergency Response

In the event of an overdose of this fixed-dose combination (Atorvastatin and Clopidogrel), the official regulatory profile focuses on two separate, severe risk domains: hemorrhagic complications and organ toxicity. No specific antidotes are known for the statin component, and treatment is symptomatic and supportive. Hemodialysis is not expected to significantly enhance clearance of the statin due to its plasma protein binding.

Documented Overdose Manifestations and Actions

Domain Manifestations and Severe Outcomes Immediate Regulatory Action
Hemorrhagic Severe bleeding or hemorrhage; Symptoms of Thrombotic Thrombocytopenic Purpura (TTP), a serious, sometimes fatal event. Seek immediate medical attention for TTP symptoms; Exogenous platelets may be administered to restore hemostasis.
Muscle/Hepatic Myopathy (muscle pain, weakness) often with markedly elevated creatine kinase (CK) levels; Progression to Rhabdomyolysis (severe muscle breakdown) which can cause acute kidney injury; Rare cases of fatal and non-fatal hepatic failure. Promptly report muscle symptoms or signs of hepatic injury (e.g., jaundice); Product discontinuation is mandated if myopathy is suspected or severe injury is confirmed.

Population-specific overdose notes indicate that advanced age (65 years or greater) and pre-existing renal impairment are documented risk factors for the severity of statin-related muscle toxicity. These documented manifestations and required actions establish the conditions under which urgent medical help must be sought.

Therapeutic Uses of Clopitab CV

Clopitab CV is a combination medicine containing clopidogrel and low-dose aspirin (acetylsalicylic acid), a therapy relevant in contexts involving heightened systemic burden. This supportive therapeutic approach is commonly used across conditions presenting with acute episodes where supportive relief is needed.

This fixed-dose combination is applied across domains where additional symptomatic support is needed for patients with Acute Coronary Syndrome (ACS). This condition involves episodic or fluctuating manifestations, and the category typically includes cases such as unstable angina and certain types of myocardial infarction. The medicine is used in clinical scenarios involving recurrent or episodic manifestations to address symptoms related to inflammatory or irritative states.

Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

By applying across domains where additional symptomatic support is needed, the medication supports patients during episodes of heightened discomfort. This approach may assist with maintaining functional stability in the context of secondary prevention. This supportive relief may help patients cope more steadily with symptom fluctuations. The medicine provides support that helps ease the overall symptom burden, and generally contributes to easing the overall symptom load during periods of heightened discomfort.

Regulatory References

  1. European Medicines Agency (EMA) DuoPlavin overview

Eligibility and Restrictions for Use

Clopitab CV is officially intended for use in the adult population. The medication is subject to formal restrictions and absolute contraindications established by regulatory authorities for the two combined components, Atorvastatin and Clopidogrel.

Populations Excluded from Use

Population Status Official Eligibility Restriction
Active Bleeding Contraindicated (Absolute Prohibition)
Active Liver Disease Contraindicated (Absolute Prohibition)
Pregnancy/Lactation Contraindicated (Use is advised against or requires discontinuation for most patients)
Pediatric Patients Use is Not Established or Not Recommended

Use is strictly prohibited for patients with pre-existing active pathological bleeding (such as peptic ulcers or intracranial hemorrhage) due to the antiplatelet component. It is also contraindicated in patients with active liver disease or unexplained, persistent elevations in hepatic transaminase levels.

Conditional Use and Restrictions

Certain groups require conditional use or heightened caution as stipulated in the official labeling. This includes patients with severe renal impairment and those with predisposing factors for myopathy (muscle disorder), such as uncontrolled hypothyroidism or advanced age (ge 65 years). These conditions increase the potential for risks associated with the statin component, requiring close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for this combination product focuses on two primary risks: drug-induced reduction in antiplatelet effect and increased risk of bleeding.

Interaction Type Interacting Products/Classes Regulatory Constraint/Note
Reduced Efficacy Risk Strong or Moderate CYP2C19 Inhibitors (e.g., Omeprazole, Esomeprazole) Avoid concomitant use as they significantly reduce the active metabolite of the antiplatelet component.
Opioids May lead to decreased exposure to the antiplatelet component; consider a parenteral antiplatelet agent.
Increased Bleeding Risk Oral Anticoagulants (e.g., Warfarin) Not recommended due to increased intensity and risk of bleeding.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), SSRIs, SNRIs, Heparin Use with caution due to an additive pharmacodynamic effect that increases the risk of bleeding.
Metabolic Impact CYP2C8 Substrates (e.g., Repaglinide) Caution is required, as the antiplatelet component may increase the plasma concentration of these substrates.

For patients requiring surgery, official guidance recommends discontinuing the antiplatelet component of the product 5 to 7 days prior to elective surgery that has a major risk of bleeding. Furthermore, the efficacy of the antiplatelet component can be affected by genetic variations in CYP2C19 function; for poor metabolizers, an alternative treatment may be considered.

Mechanism of Action

The mechanism of Clopitab CV involves two complementary pharmacodynamic domains. The Atorvastatin component acts as a competitive inhibitor of the HMG-CoA Reductase enzyme in the liver, blocking the rate-limiting step in the Mevalonate pathway to reduce endogenous cholesterol synthesis. This physiological response increases LDL receptor expression, enhancing the clearance of low-density lipoprotein cholesterol ( LDL-C) from systemic circulation. The second domain involves the Clopidogrel active metabolite functioning as an irreversible antagonist of the P2Y12 receptor on blood platelets. This receptor blockade impairs the crucial ADP-mediated signaling cascade that activates the GP IIb/IIIa complex, thereby reducing the ADP-dependent platelet aggregation response and impairing primary hemostasis. The drug provides a coordinated physiological effect: one component modulates lipid homeostasis by influencing circulating lipoproteins, while the other provides functional constraint on the hemostatic system through P2Y12 antagonism. This dual pathway modulation establishes a combined physiological effect across multiple systems.

Dosage and Administration Information

Official Dosing and Administration Protocol

Clopitab CV is administered solely via the oral route as a fixed-dose combination (FDC) tablet. The standard regimen consists of taking a single tablet once daily. This FDC format is specifically utilized for the continuation of therapy in adult patients who have already been stabilized on the individual component medicines, clopidogrel and acetylsalicylic acid (ASA). The strengths for this combination typically include 75 mg clopidogrel combined with either 75 mg or 100 mg of ASA.

Timing and Duration of Use

The administration is flexible concerning mealtimes, as the tablet may be taken with or without food. This daily regimen is intended to support long-term antiplatelet management, with clinical data supporting its use for up to 12 months in certain patient populations.

Proper usage includes strict guidance for maintaining continuous coverage. If the daily dose is missed by less than 12 hours, it should be taken immediately, and the subsequent dose should be taken at the usual scheduled time. If the delay is more than 12 hours, the missed dose is skipped entirely to prevent double-dosing, and the regimen is resumed at the next regularly scheduled time. The medicine is not recommended for paediatric patients, and it must not be used in patients with severe hepatic or severe renal impairment.

Recent Clinical Evidence

Research Focus: Combination Therapy

Clopitab CV is a fixed-dose combination (FDC) therapy containing Clopidogrel (an antiplatelet agent) and Atorvastatin (a statin for cholesterol management). Clinical research has primarily centered on evaluating the benefits and safety of co-administering these two agents, particularly in patients with acute coronary syndrome (ACS) or those undergoing percutaneous coronary intervention (PCI).

Randomized controlled trials (RCTs) have consistently evaluated the combination's impact on reducing the risk of major cardiovascular events, such as heart attack and stroke, in comparison to other therapeutic regimens. These studies form the core body of evidence supporting its use in cardiovascular disease management.

Findings on Drug Interaction and Platelet Activity

A central focus of evidence review has been a potential drug-drug interaction, as both components are metabolized by hepatic cytochrome P450 enzymes. Early studies, often conducted ex vivo (in lab settings), suggested that Atorvastatin might reduce the antiplatelet effect of Clopidogrel by interfering with its metabolic activation.

However, larger clinical outcome trials and their secondary analyses have generally not demonstrated a significant negative impact on major clinical endpoints (e.g., mortality, non-fatal heart attack) when the two drugs are co-administered. The results regarding antiplatelet activity have been mixed and may be dependent on dosing, timing, and individual patient factors.

Safety and Long-term Monitoring

Long-term studies have examined the combined safety profile, focusing on adverse events commonly associated with each component, such as bleeding (from clopidogrel) and muscle-related issues (from atorvastatin). While the combination is widely used, ongoing investigations continue to monitor its long-term impact on different patient populations and its influence on other clinical markers.

Frequently Asked Questions (FAQ)

Common questions about Clopitab CV (FAQ)

Q: What is Clopitab CV used for?

Clopitab CV is a combination medicine containing Clopidogrel and Aspirin (Acetylsalicylic Acid). According to official product information, it is used to help reduce the risk of serious cardiovascular events such as heart attacks and strokes in people who have existing heart or circulatory conditions. It works by helping to prevent the formation of blood clots.

Q: How does Clopitab CV work in the body?

Clopitab CV contains two active ingredients that work together to prevent blood clots. Aspirin is an antiplatelet agent that affects how platelets (tiny blood cells) stick together, and Clopidogrel provides a separate antiplatelet action that enhances this effect. Studies and official information indicate this dual action helps to keep the blood flowing smoothly and reduces the risk of unwanted clotting in the arteries.

Q: Can I stop taking Clopitab CV when I feel better?

Regulatory documents state that this medicine is typically prescribed for the full duration determined by a healthcare professional. Official documentation indicates that abrupt discontinuation of treatment may increase the risk of serious cardiovascular events. Any decision regarding stopping or changing treatment should be made in consultation with a prescribing healthcare professional.

Q: Does Clopitab CV affect blood pressure?

While the primary action of Clopitab CV is on blood clotting, official information does not list it as a medication specifically intended to treat or lower high blood pressure. However, it is a crucial medicine for people with certain heart and circulatory conditions where blood pressure management is also important. Concerns about blood pressure should be addressed with a healthcare provider.

Q: Is Clopitab CV safe for long-term use?

According to the official product information, Clopitab CV is often prescribed for long-term use to continuously prevent blood clots and major cardiac events in people at risk. The necessity and duration of treatment are determined by a healthcare provider based on the individual's specific medical history. Individuals on long-term therapy are typically advised to maintain regular follow-up appointments.

Q: What should I do if I miss a dose of Clopitab CV?

Regulatory documents describe the procedure for a missed dose, which is generally to take it promptly if remembered, unless it is almost time for your next scheduled dose, in which case the missed dose should be skipped. It is advised not to take a double dose to compensate for the one that was missed. Patients should refer to the full product label for detailed instructions.

Q: Can I drink alcohol while taking Clopitab CV?

Official guidance states that excessive alcohol consumption is generally not recommended while taking Clopitab CV. Alcohol may increase the risk of certain side effects, particularly bleeding in the stomach or gut, due to the Aspirin component of the medicine. Consumption of alcohol should be reviewed with a prescribing healthcare professional.

Q: Does Clopitab CV need to be taken with food?

Official product information states that Clopitab CV can generally be taken with or without food. However, some people may find that taking it with a meal or a glass of water helps reduce the potential for stomach upset. Patients are directed to follow the specific instructions provided by their prescribing professional.

How should Clopitab CV be stored and disposed of?

How to Store and Dispose of Clopitab CV?

  • Storage: Clopitab CV should be stored in its original packaging at room temperature, typically below 25 C (or below 30 C as indicated on the package), in a clean, dry place. It must be protected from excessive moisture, heat, and direct light.

  • Safety: Always ensure the medication is kept completely out of the sight and reach of children and pets to prevent accidental ingestion.

  • Disposal: Do not use this medicine past the expiration date. Unused or expired medication should not be flushed down a toilet or poured into a drain. To properly and safely discard Clopitab CV, follow local drug take-back programs or consult your pharmacist for guidance on environmentally responsible disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clopitab CV found in:

A-Z Index: